Los Angeles Talc Verdicts Split — What the 2026 Outcomes Mean for Your Family
If you are reading this at 2 a.m. because someone you love used Johnson’s Baby Powder for decades and then heard the word mesothelioma — or ovarian cancer — from an oncologist who looked like they had been carrying that word a long time, you are in the right place. Not because what happened to your family is simple. It is not. It is one of the largest, most complicated mass torts in American history, with more than 68,000 lawsuits still pending, and the verdicts coming out of courtrooms right now are splitting in opposite directions. Four days apart, in the same Los Angeles courthouse, one jury awarded $32 million to a family that lost their mother to mesothelioma, and another jury cleared the same company of negligence in an ovarian cancer case. That is not a contradiction a marketing page can smooth over. It is the reality of this litigation, and you deserve to understand it before you make a single decision.
We are Attorney911 — The Manginello Law Firm. We handle toxic tort and product liability cases in California, and what we do on this page is give you the straight, complete analysis of what these split verdicts mean. Not a sales pitch. Not a guarantee. The law, the science, the evidence clock, and the honest range of what a case like yours is worth — including the real possibility that a jury says no. Ralph Manginello has spent 27-plus years in courtrooms, including federal court, and before he was a lawyer he was a journalist — which means he would rather give you an uncomfortable truth than a comfortable lie. Lupe Peña spent years inside a national insurance-defense firm, in the rooms where claims like yours are priced and devalued, before he came to our side of the table. He speaks fluent Spanish and conducts full consultations without an interpreter. Everything we tell you here is what we would tell you across a kitchen table, with your family’s future on it.
The $32 Million Verdict for Maria Lozano’s Family — What a Los Angeles Jury Decided on June 9, 2026
On June 9, 2026, a Los Angeles Superior Court jury awarded $32 million to the family of Maria Lozano, who died from pleural mesothelioma in 2024. Her children continued the lawsuit after her death. The trial evidence showed that Lozano had used Johnson & Johnson baby powder for decades, beginning in the 1970s — a period of use stretching more than fifty years before her death. The jury rejected Johnson & Johnson’s argument that Lozano’s asbestos exposure may have originated from environmental sources during her childhood in Mexico City. Instead, they found the company solely responsible for her mesothelioma.
That last sentence is the one that matters most. J&J’s defense in mesothelioma talc cases frequently argues that the asbestos exposure came from somewhere else — the environment, a different occupation, a different product. The Lozano jury heard that argument and rejected it. They looked at decades of baby powder use and decided that was the cause, not the air in Mexico City decades earlier. That is a specific-causation finding, and it is exactly the battleground every talc mesothelioma case is fought on.
The $32 million figure sits within the range that contemporary talc verdicts have established in California. In December 2025, another Los Angeles jury awarded approximately $40 million to ovarian cancer plaintiffs in a bellwether trial. These two verdicts — one for mesothelioma, one for ovarian cancer — set the upper end of what Los Angeles juries have been willing to do when they find the causal connection persuasive. But they are not the whole story. They are half of it.
Defense Verdicts in Oklahoma and Los Angeles — Why Juries Disagree on Talc and Cancer
Four days before the Lozano verdict, on June 5, 2026, a different Los Angeles jury returned a 10-2 defense verdict for Johnson & Johnson and co-defendant Red River Talc LLC in a bellwether ovarian cancer trial involving the families of three women — Mary Owens, Bonnie Tienken, and Geneva Williams — who alleged decades of talcum powder use caused their ovarian cancers. After a six-week trial, the jury found that J&J was not negligent in the manufacture or sale of its talc products and that the plaintiffs had failed to prove the company’s products caused the women’s cancers. J&J’s vice president of litigation publicly called the plaintiffs’ case “junk science.”
Weeks earlier, in May 2026, an Oklahoma County District Court jury delivered another defense verdict in a mesothelioma case. The plaintiff, Kathryn Passmore-Meyer, alleged she developed malignant mesothelioma after decades of exposure to asbestos-contaminated talc products, including Johnson’s Baby Powder and Shower to Shower. The jury found that the plaintiff failed to establish manufacturer liability against J&J and concluded the company was neither negligent nor reckless.
So within a span of roughly six weeks, in three different trials, the same company faced the same general theory of liability — that its talc products were contaminated with asbestos and caused cancer — and got three completely different outcomes: one $32 million plaintiff verdict, one 10-2 defense verdict, and one total defense verdict. The Pennsylvania appellate court also affirmed a prior defense verdict in an ovarian cancer case around the same period, adding further support to J&J’s litigation position.
Here is why that happened, and why it matters for your family.
Venue and jury composition are decisive. Los Angeles Superior Court is a major venue for product liability bellwether trials. Its jury pool is large and diverse, and it has produced both substantial plaintiff verdicts and defense verdicts depending on the specific scientific evidence presented. Oklahoma County District Court, by contrast, draws from a more conservative jury demographic that tends to scrutinize novel scientific causation theories closely. The contrast between the Oklahoma mesothelioma defense verdict and the Los Angeles mesothelioma plaintiff verdict — same disease, same defendant, same general theory — is a direct illustration of how venue selection and jury composition influence outcomes in toxic tort litigation. The Los Angeles Complex Litigation departments handle these high-stakes mass tort cases with sophisticated case management procedures, which means the quality of the presentation matters as much as the underlying facts.
Disease type changes the scientific battleground. The $32 million Lozano verdict was a mesothelioma case. The June 5 defense verdict was an ovarian cancer case. These are scientifically different fights, and the difference is the single most important thing to understand about talc litigation.
Mesothelioma vs. Ovarian Cancer Talc Cases — Why the Disease Type Changes Everything
If your family is dealing with mesothelioma, the scientific road to causation is shorter and more established. Mesothelioma is a cancer of the lining of the lungs (pleural) or abdomen (peritoneal), and it is essentially specific to asbestos exposure. The medical literature has established this connection for decades. The International Agency for Research on Cancer classifies asbestos as a Group 1 known human carcinogen. The latency period — the time between first exposure and diagnosis — is typically 20 to 50 years, with most cases appearing 30 to 40 years after exposure. That long latency is why someone who used baby powder in the 1970s might not be diagnosed until 2024, exactly as happened with Maria Lozano.
The defense fight in a mesothelioma case is not usually about whether asbestos causes mesothelioma — everyone agrees it does. The fight is about specific causation: whether this patient’s mesothelioma was caused by asbestos in this company’s talc, or whether the exposure came from somewhere else. That is exactly the fight the Lozano jury resolved in the plaintiff’s favor, and exactly the fight the Oklahoma jury resolved in J&J’s favor. Same science, different jury, different result.
If your family is dealing with ovarian cancer, the road is harder. The causal pathway between talc use and ovarian cancer is more contested in the scientific literature. While some epidemiological studies have found an association between genital talc use and ovarian cancer, the defense argues vigorously that the evidence is not strong enough to prove causation in an individual case. This is why J&J’s reported trial record shows better outcomes in ovarian cancer cases than in mesothelioma cases, and why the June 5 Los Angeles defense verdict was an ovarian cancer case while the June 9 plaintiff verdict was mesothelioma.
This does not mean ovarian cancer cases are unwinnable. The approximately $40 million December 2025 Los Angeles verdict was an ovarian cancer case. But it does mean that the strength of your case depends heavily on which disease your family is facing, and the defense strategy shifts accordingly.
California Strict Product Liability — The Law That Governs Talc Cases in Los Angeles
California applies strict product liability under the framework adopted in landmark state precedent, imposing liability on manufacturers for defective products without requiring proof of negligence. This means that in California, you do not have to prove Johnson & Johnson was careless — you have to prove the product was defective and that the defect caused the injury. There are three primary theories under which talc cases proceed:
Design defect. Plaintiffs allege that cosmetic talc products were inherently defective because they contained asbestos fibers, a known carcinogen, making the products unreasonably dangerous for their intended use. Under California’s risk-benefit test, a product is defective in design if the danger could have been reduced by a reasonable alternative design — and the obvious alternative for talc is cornstarch, which J&J itself ultimately used in some markets.
Failure to warn. Plaintiffs contend J&J failed to warn consumers of alleged asbestos contamination and cancer risk despite purported internal knowledge dating to the 1960s. The absence of any cancer or asbestos warning on product labels for decades is central to this theory. California law holds that a manufacturer has a duty to warn of known or reasonably foreseeable dangers — and a company that allegedly knew of contamination for decades and said nothing faces a severe failure-to-warn claim.
Fraudulent misrepresentation and concealment. Plaintiffs allege J&J knowingly misrepresented the safety of its talc products and concealed internal testing data showing asbestos contamination. This theory is critical because it supports not just compensatory damages but punitive damages.
Cosmetic talc products fall under FDA regulation pursuant to the Federal Food, Drug, and Cosmetic Act, though historically cosmetics have not required premarket FDA approval or mandatory asbestos testing — a regulatory gap central to plaintiffs’ failure-to-warn arguments.
That regulatory gap is the backbone of the failure-to-warn theory. The federal government never required cosmetic talc to be tested for asbestos. J&J argues that compliance with existing cosmetic regulatory standards means it did nothing wrong. Plaintiffs argue that regulatory compliance does not absolve a manufacturer of the duty to warn of known or foreseeable dangers beyond what regulations require — and that a company with internal testing data going back decades cannot hide behind the absence of a federal testing mandate.
California does not impose statutory caps on compensatory or punitive damages in product liability cases. This is one of California’s strongest advantages for plaintiffs. Unlike states that cap non-economic damages, California allows a jury to award what it finds the harm to be worth — in both compensatory and punitive categories. Punitive damages are available upon a showing of malice, oppression, or fraud by clear and convincing evidence. The concealment theory — if proven — is exactly the kind of conduct that opens the door to substantial punitive awards.
California follows a pure comparative negligence regime. This means that even if a jury finds the plaintiff partially at fault, recovery is reduced by the allocated percentage but never barred entirely. In practice, this matters less in talc cases (where the plaintiff’s “fault” is usually minimal — they used a cosmetic product as directed), but it means that being a long-time smoker or having other risk factors does not automatically destroy your case.
California’s Statute of Limitations — The Clock That Kills Cases Silently
California’s statute of limitations for personal injury and wrongful death actions is two years. For personal injury, the clock generally starts when the injury is discovered or should have been discovered. For wrongful death, it starts from the date of death. In toxic tort cases involving latent diseases like mesothelioma and ovarian cancer, the discovery rule is critical — the clock may not start running until the plaintiff knew or should have known of the injury and its connection to the exposure.
For mesothelioma with a 20-to-50-year latency, this means the two-year clock likely starts around the date of diagnosis, not the date of exposure decades ago. For ovarian cancer, the same discovery principle applies, though the causal connection is more contested and the “should have known” analysis may be more complicated.
Do not assume you have plenty of time. The two-year period can pass faster than families expect, especially when a loved one’s illness consumes every waking moment. And some states have statutes of repose — outer deadlines that can cut off a claim even before discovery — though California’s product liability framework generally does not impose a hard repose period for latent disease cases. Still, the only safe move is to have the deadline checked by an attorney in your state as soon as possible.
If your loved one has already passed away, the wrongful death clock started on the date of death. If the diagnosis was recent, the personal injury clock may have started on or near the diagnosis date. Either way, the deadline is measured in years, not decades — and the evidence is measured in months, not years.
Who Is Johnson & Johnson — The Corporate Structure Behind 68,000 Lawsuits
Johnson & Johnson is not a single company. The talc liability has been shuffled through a chain of entities, and understanding this structure is essential to understanding why these cases are fought the way they are.
Johnson & Johnson is the parent corporation — a global pharmaceutical and consumer products giant. Johnson & Johnson Consumer Inc. (JJCI) was the historical talc seller. LTL Management LLC was the entity created in a divisional merger — sometimes called the “Texas two-step” — to hold talc liability, and it filed for Chapter 11 bankruptcy twice. Both attempts were dismissed by the courts. Red River Talc LLC — the entity that appears as a co-defendant in the June 5, 2026 Los Angeles bellwether defense verdict — was the renamed successor liability vehicle used for a third bankruptcy attempt. That attempt was also denied and dismissed by the U.S. Bankruptcy Court for the Southern District of Texas on March 31, 2025, after the court found vote-solicitation irregularities and impermissible nonconsensual third-party releases.
Kenvue Inc. is the consumer-health spinoff (brands including Band-Aid, Tylenol, Listerine) that J&J separated into a distinct public company. J&J has indemnity arrangements with Kenvue, but Kenvue is a separate corporate entity.
Three times J&J tried to wall these cases off inside a bankruptcy it created on purpose. Three times a court threw that out. The cases are back in the regular court system — all 68,000-plus of them, consolidated in the Multi-District Litigation before Judge Michael A. Shipp in the District of New Jersey (MDL-2738), with more than 68,000 actions pending as of mid-2026.
The corporate structure matters because it affects who you sue, who pays, and what insurance tower is available. A plaintiff who names only “Johnson & Johnson” without identifying the correct operating entity, the liability vehicle, and the corporate parent may find the real defendant arguing it was never properly served. This is the kind of detail that separates a case that moves forward from a case that gets dismissed on a technicality.
The Evidence Clock — What Proof Exists and How Fast It Disappears
The evidence in a talc case is not like the evidence in a car crash. There is no skid mark to measure, no dashcam to pull, no police report filed within 24 hours. The evidence is spread across decades — across homes that may have been moved out of, hospitals that may have purged records, and products that may have been thrown away. And much of it is on a clock.
Talc product containers and remaining powder samples. If your family still has the actual Johnson’s Baby Powder container — any container, from any decade — that physical product can be tested for asbestos fiber content using transmission electron microscopy (TEM) and other analytical methods. This is the single most powerful piece of specific-causation evidence in a talc case: a product container from your loved one’s bathroom, tested in a laboratory, showing asbestos fibers in the powder they actually used. But product containers are routinely discarded by family members, lost during moves, or thrown away after the user’s death. If any container survives, it should be secured immediately and stored properly — do not open it, do not shake it, do not let anyone “check” it without a chain of custody.
Decedent’s pathology tissue blocks and slides. Lung tissue or tumor tissue from a biopsy, surgery, or autopsy can be analyzed for asbestos fiber type and count. This is what supports specific causation by identifying talc-associated fibers distinct from background environmental exposure. It is the medical evidence that distinguishes “this came from baby powder” from “this came from the air in Mexico City.” But hospital pathology departments may purge tissue blocks after their statutory retention period expires. A written request to preserve the tissue blocks should be sent to the treating hospital’s pathology department immediately — not after you hire a lawyer, not after you decide whether to file suit, but now.
Complete medical and oncology records including diagnostic imaging. These document the disease trajectory, the treatment course, the medical costs, and the temporal relationship between the exposure period and the cancer diagnosis. Medical records are generally retained per state statutory requirements, but providers close, merge, and purge. Obtain them promptly while the facilities and providers are identifiable.
Exposure history documentation — receipts, photographs, witness statements. This is what proves the duration, frequency, and specific products used over decades. Family photographs showing a bathroom shelf with Johnson’s Baby Powder on it. Receipts from decades of purchases. The testimony of a sister who remembers her mother powdering herself every morning for thirty years. Witnesses age and memories fade. Receipts get thrown away. Family members should be interviewed while recollections are fresh — not in six months, not after the funeral arrangements are finalized, but while the details are still vivid.
J&J corporate documents produced in MDL discovery. Internal testing results, memos, emails, and regulatory correspondence already produced in the MDL provide critical evidence of knowledge, concealment, and punitive damages predicates. These documents are already preserved in the MDL record, but case-specific document selection and expert analysis require months of preparation before trial. The MDL has produced extensive corporate document discovery, including internal J&J testing data and communications, that plaintiff firms leverage rather than duplicate.
The fastest-dying evidence in a talc case is the physical product and the pathology tissue. The product can be thrown away by a family member who does not know it is evidence. The tissue can be purged by a hospital that does not know anyone will ever ask for it. Both of those things can happen within weeks — and once they happen, they cannot be undone.
What Talc Cases Are Worth — From the $32M Lozano Verdict to the Defense Verdict Risk
We are not going to give you a number and call it a promise. That would be dishonest. What we will give you is the verified range of what these cases have actually produced, and the honest truth about what drives the number up or down.
The established California verdict benchmarks. The $32 million Lozano mesothelioma verdict (June 2026) and the approximately $40 million December 2025 Los Angeles ovarian cancer verdict establish the upper range for California verdicts in the current litigation environment. These are real numbers from real juries in the courthouse where your case would likely be filed if you live in Los Angeles County.
The defense verdict risk is real. The June 5, 2026 Los Angeles defense verdict and the May 2026 Oklahoma defense verdict demonstrate that juries frequently reject causation evidence entirely, producing zero-recovery outcomes. J&J reports it has won approximately 20 ovarian cancer trials and lost roughly 12, though exact totals vary depending on how mistrials, retrials, consolidated cases, and appellate reversals are counted. Several large plaintiff verdicts have also been reduced or overturned after appeal.
The established historical benchmark. The largest talc verdict to survive appeal is the Ingham v. Johnson & Johnson case, in which a Missouri jury awarded $4.69 billion in 2018. The Missouri Court of Appeals reduced that to approximately $2.12 billion in 2020, and the U.S. Supreme Court declined to review the reduction in June 2021 — meaning the approximately $2.1 billion award stands as final. That is the headline number, but it came from 22 plaintiffs consolidated in a single trial, and it was cut nearly in half on appeal. A single-plaintiff case does not produce a $2 billion verdict.
The case value range for individual cases. Based on the current litigation environment — the $32M Lozano verdict, the approximately $40M December 2025 verdict, the defense verdict risk across multiple venues, and J&J’s demonstrated willingness to try cases — the realistic range for an individual talc cancer case runs from approximately $3 million on the low end to $45 million on the high end. The low end reflects settlement leverage, not trial outcomes. Mesothelioma cases generally carry higher value than ovarian cancer cases due to the more established scientific link between asbestos exposure and mesothelioma, though both disease categories have produced both plaintiff verdicts and defense verdicts.
What drives the number. A strong mesothelioma case with clear product identification (you have the actual container or a long, well-documented history of use), long-duration exposure (decades, not months), and a jury in a favorable venue like Los Angeles is at the upper end. A weaker case — uncertain product identification, short exposure duration, ovarian cancer rather than mesothelioma, or a conservative venue — is at the lower end or may produce a defense verdict. The presence of internal J&J documents showing knowledge and concealment, if applicable to your specific case, can drive punitive damages substantially higher.
Past results depend on the facts of each case and do not guarantee future outcomes. That is not a disclaimer we put in fine print. It is the truth, and it is exactly what the split verdicts of 2026 prove.
The Defense Playbook — How J&J Fights Talc Cases and What We Do About It
Johnson & Johnson is represented by some of the most sophisticated defense lawyers in the world. They have tried these cases dozens of times. They know what works and what does not, and they deploy a consistent set of strategies. Here are the plays and the counters:
Play 1: The “junk science” attack. J&J’s vice president of litigation publicly called the plaintiffs’ case “junk science” after the June 5 defense verdict. The defense strategy is to frame the causal link between cosmetic talc and cancer as unproven, fringe science that does not meet the legal standard for reliable evidence. They challenge the admissibility of plaintiff experts under the Daubert standard, trying to exclude their testimony before the jury ever hears it. Counter: The asbestos-mesothelioma link is not junk science — it is established medical fact recognized by the IARC, the CDC, and decades of peer-reviewed literature. The fight is not about whether asbestos causes mesothelioma; it is about whether the asbestos was in the talc. That is a product-testing and exposure-history question, not a novel-science question. For ovarian cancer, the causation evidence is more contested, and the expert selection and Daubert fight is harder — but it is winnable, as the December 2025 $40 million verdict shows.
Play 2: The alternative exposure defense. In the Lozano case, J&J argued that her asbestos exposure may have originated from environmental sources during her childhood in Mexico City. This is their go-to defense in mesothelioma cases — find another source of asbestos exposure and argue that that was the cause, not the baby powder. Counter: Differential etiology — the medical process of eliminating alternative causes — is how you beat this. If the pathology tissue can be analyzed for fiber type, and the fibers found are consistent with the type of asbestos found in talc deposits (as opposed to the type found in ambient urban air), the alternative-exposure argument weakens. The Lozano jury heard the Mexico City argument and rejected it. That is the template.
Play 3: The bankruptcy strategy. J&J created LTL Management LLC and then Red River Talc LLC to hold talc liability and filed for Chapter 11 bankruptcy three times — attempting to freeze all litigation and force plaintiffs into a global settlement through the bankruptcy court. All three attempts were dismissed by the courts. Counter: The bankruptcy dismissals are themselves evidence — evidence that J&J attempted to use a corporate maneuver to avoid facing juries. Courts found vote-solicitation irregularities and impermissible nonconsensual third-party releases. The fact that J&J tried this three times, and failed three times, tells a jury something about the company’s approach to these cases.
Play 4: The venue strategy. J&J seeks favorable jury pools and points to its defense wins in conservative venues like Oklahoma County as evidence that juries reject plaintiffs’ theories. Counter: The same company lost a $32 million verdict in Los Angeles four days after winning a defense verdict in the same courthouse. Venue matters, but so does the evidence. In California — where there are no caps on compensatory or punitive damages, where strict product liability is well-established, and where the jury pool is diverse — a well-prepared case with strong specific-causation evidence can win.
Play 5: The quick settlement offer. In mass torts, defendants sometimes offer fast settlements to weaker cases — not because they are generous, but because settling a weak case for a modest amount is cheaper than trying it and setting a bad precedent. But they will not settle a strong case cheaply, and they will not settle at all if they believe they can win at trial. Counter: Understanding the difference between a case J&J wants to settle and a case J&J wants to try is everything. Lupe Peña sat in the rooms where these decisions were made on the defense side. He knows the signals — the reserve set in the first 48 hours, the timing of the first offer, the difference between a carrier’s first number and its walk-away number. That knowledge is what prevents a family from accepting a fraction of what their case is worth.
How a Talc Case Is Actually Built — From First Call to Verdict
Here is what happens when a family calls us about a talc-related cancer diagnosis. Not what we promise — what we actually do.
Week one: the preservation letter. The first document that goes out is a litigation-hold and spoliation letter — not to J&J, but to the hospital pathology department, ordering them in writing to preserve all tissue blocks, slides, and pathology specimens from your loved one’s diagnosis. This letter also goes to any facility that may hold medical records, imaging, or exposure documentation. The reason it goes out in week one is that pathology tissue can be purged on a hospital’s retention schedule — and once it is gone, the single best piece of specific-causation evidence is gone with it.
Weeks one through four: evidence inventory. We sit down with the family — in English or in Spanish, whichever is more comfortable — and we build the exposure history. What products? What brands? How often? Starting when? Ending when? Applied where on the body? We look for photographs, receipts, old bathroom shelves, anything that documents the use pattern. We identify witnesses — family members, friends, coworkers who might have seen the product in the home. We secure any surviving product containers.
Months one through three: medical record assembly and expert selection. We obtain the complete medical and oncology record — diagnostic imaging, pathology reports, treatment records, medical bills, everything. We begin selecting experts: a board-certified pathologist to analyze the tissue for asbestos fibers, a toxicologist to opine on exposure and dose, an oncologist to address specific causation, and where applicable, a life-care planner and forensic economist to build the damages model.
Months three through twelve: case-specific discovery and MDL leverage. We do not reinvent the wheel. The MDL has produced extensive corporate document discovery — internal J&J testing data, communications, regulatory correspondence — that we leverage rather than duplicate. Our case-specific discovery focuses on your loved one’s exposure timeline, product identification, and differential etiology excluding alternative asbestos sources. We serve discovery on the correct J&J entity — Johnson & Johnson Consumer Inc., Red River Talc LLC, and the parent corporation, depending on the exposure period and the corporate structure in effect at the time.
Pretrial: the Daubert fight. Before the jury ever hears the case, the defense will move to exclude our experts under the Daubert standard — arguing that their methodology is unreliable or their opinions are not based on sufficient data. This is where cases are won and lost before they begin. The strength of our expert panel — their credentials, their methodology, their ability to withstand cross-examination — is the difference between a case that reaches a jury and one that is dismissed on a motion.
Trial: the causation battle. If the case goes to trial, everything reduces to one question: did this product cause this cancer? The defense will present its alternative-exposure theories, its junk-science framing, its experts challenging every link in the causal chain. We present our product-testing evidence, our pathology analysis, our exposure history, and the corporate documents showing what J&J knew and when. The jury decides.
This process takes months to years. It is not fast. But the evidence clock means that the first weeks — the preservation letter, the evidence inventory, the tissue preservation demand — are the weeks that decide whether the case can be built at all.
What to Do in the First 72 Hours — Evidence Preservation Steps
If you or a loved one has been diagnosed with mesothelioma or ovarian cancer and has a history of long-term talcum powder use, the most important steps are the ones you take before any lawsuit is filed.
Secure any remaining talc product containers. If there is a Johnson’s Baby Powder container, a Shower to Shower container, or any other talc-based powder product in the home — do not throw it away, do not open it, do not shake it, do not let anyone “test” it informally. Place it in a sealed bag and store it in a dry, safe location. This container is physical evidence that can be tested for asbestos content using transmission electron microscopy.
Request pathology tissue preservation in writing. Contact the hospital or pathology department that performed the biopsy, surgery, or autopsy and send a written request that all tissue blocks, slides, and specimens be preserved indefinitely and not destroyed or discarded. Follow up to confirm receipt. Hospitals purge tissue on retention schedules — a written preservation request can stop that clock.
Gather medical records. Obtain copies of all diagnostic imaging, pathology reports, oncology records, treatment summaries, and medical bills. If your loved one has passed away, request the death certificate and any autopsy report.
Document the exposure history. Write down everything you can remember about the talc use: the brand, the frequency, the duration, the start and end dates, where it was applied on the body. Ask family members to do the same. Look for old photographs, receipts, or anything that shows the product in the home. Do this while memories are fresh — not in six months.
Do not give a recorded statement to anyone. If you are contacted by anyone representing Johnson & Johnson, its insurers, or any third party asking for a statement about your loved one’s product use or medical history — do not speak with them. Refer them to an attorney. Anything you say can and will be used to build the alternative-exposure defense.
Do not sign anything. If you are offered a settlement or asked to sign a release — do not sign it. A release signed before you understand the full value of your case cannot be undone.
Call us at 1-888-ATTY-911. The consultation is free. The call is confidential. We work on contingency — 33.33% before trial, 40% if the case goes to trial. We do not get paid unless we win your case. And if we are not the right fit for your case, we will tell you.
The United Kingdom Action — 7,111 Claimants and Growing
While U.S. talc litigation continues to produce mixed verdicts, Johnson & Johnson also faces a growing legal challenge in the United Kingdom. In June 2026, a case before the High Court expanded to 7,111 claimants, making it the largest product liability action in U.K. history. The claimants — many of whom have ovarian cancer or mesothelioma — contend that J&J knew as early as the 1960s that its talc products contained contaminants linked to cancer and failed to warn consumers. J&J denies the allegations and maintains that its baby powder complied with regulatory standards, did not contain asbestos, and does not cause cancer. The U.K. case remains in its early procedural stages and is expected to take years to resolve.
The 7,111-claimant U.K. action and the more than 68,000 pending U.S. MDL cases together underscore the global reach of talc litigation against Johnson & Johnson. This is not a closed chapter. It is an active, ongoing fight.
Frequently Asked Questions
How long do I have to file a talc lawsuit in California?
California’s statute of limitations for personal injury and wrongful death actions is two years. In toxic tort cases involving latent diseases like mesothelioma and ovarian cancer, the discovery rule may mean the clock starts when you knew or should have known of the injury and its connection to talc exposure — not when the exposure occurred decades ago. For wrongful death, the clock starts from the date of death. Because the rules are complex and the deadlines are unforgiving, the safest move is to have the specific deadline for your situation checked by an attorney as soon as possible.
Can I still sue if my loved one already died from mesothelioma or ovarian cancer?
Yes. California permits wrongful death actions brought by statutorily defined beneficiaries — typically the surviving spouse, children, and in some cases parents or other dependents. A survival action may also preserve claims the decedent could have pursued during life, including pre-death pain and suffering. Maria Lozano’s children continued her lawsuit after her death and obtained the $32 million verdict. The key is timing — the wrongful death clock starts on the date of death, and the evidence must be preserved before the hospital purges pathology tissue.
Does it matter whether my diagnosis is mesothelioma or ovarian cancer?
Yes, it matters significantly. Mesothelioma cases offer stronger general causation because the asbestos-mesothelioma link is scientifically well-established — mesothelioma is essentially specific to asbestos exposure. Ovarian cancer cases face a more contested causal pathway and higher defense verdict risk. However, both disease categories have produced both plaintiff verdicts and defense verdicts. The December 2025 approximately $40 million Los Angeles verdict was an ovarian cancer case, proving that substantial awards are possible — but the June 5, 2026 defense verdict was also an ovarian cancer case, proving the risk is real.
What if I don’t have the original baby powder container?
Not having the original container makes the case harder but does not make it impossible. Product identification can be established through witness testimony (family members who remember the product being used), photographs showing the product in the home, purchase receipts, and the decedent’s own statements about their habits. The pathology tissue analysis can also support specific causation by identifying asbestos fiber types consistent with talc exposure. But if you do have a container — any container — securing it is the single most important evidence step you can take.
How much is a talc cancer case worth?
The realistic range for an individual talc cancer case runs from approximately $3 million on the low end to $45 million on the high end, based on current California verdict benchmarks including the $32 million Lozano mesothelioma verdict and the approximately $40 million December 2025 ovarian cancer verdict. The low end reflects settlement leverage; the high end reflects strong trial outcomes. Defense verdicts — producing zero recovery — are also a real possibility, as demonstrated by the June 2026 Los Angeles and Oklahoma defense verdicts. The specific value of your case depends on disease type, exposure duration, product identification strength, venue, and the punitive damages potential of any concealment evidence. No attorney can guarantee a specific outcome or dollar amount. For more on how case value is determined, Ralph Manginello breaks down personal injury case valuation in a video that applies the same principles.
Why did some juries find for J&J and others for the plaintiffs?
The outcomes depend on three primary factors: disease type (mesothelioma has stronger causation than ovarian cancer), venue and jury composition (Los Angeles has produced both plaintiff and defense verdicts; Oklahoma has produced a defense verdict), and the strength of the specific causation evidence presented. The same general theory of liability can produce a $32 million verdict in one courtroom and a defense verdict in another, four days apart, because the juries heard different evidence, different experts, and different arguments about whether the talc caused the cancer. This is why case preparation — the expert selection, the evidence preservation, the exposure documentation — is the difference between winning and losing.
What if my loved one used baby powder for only a few years?
Longer, more frequent use creates a stronger exposure case. Decades of daily use — as Maria Lozano had, starting in the 1970s — is the strongest fact pattern. But shorter or less frequent use does not automatically disqualify a case. The question is whether the total exposure was sufficient to contribute to the disease. This is a medical and toxicological question that requires expert evaluation. Do not assume your case is too weak until an attorney has evaluated the specific facts.
Will my case go to trial or settle?
Some talc cases settle; others go to trial. J&J has demonstrated a willingness to try cases — it reports approximately 20 wins and 12 losses in ovarian cancer trials — and it will not settle weak cases. Settlement leverage exists primarily for strong mesothelioma cases with clear product identification and long-duration exposure. The decision to settle or try a case is strategic and depends on the strength of the evidence, the venue, the specific disease, and the defendant’s assessment of its own risk. We prepare every case as if it will go to trial, because that is the only way to command a fair settlement — and the only way to win if it does not settle.
Can I join the MDL if I live in California?
Yes. The Johnson & Johnson Talcum Powder Products MDL (MDL-2738) is centralized in the District of New Jersey, but claimants from any state — including California — can file into the MDL. Joining the MDL does not merge your case into one big pot; you keep your own claim, and the court handles the shared pretrial work in one place. If your case is not resolved through settlement or summary judgment in the MDL, it can be remanded to your home district — including the Central District of California or Los Angeles Superior Court — for trial.
What does it cost to hire a talc lawyer?
We work on contingency. The consultation is free. We do not get paid unless we win your case. If your case resolves before trial, the fee is 33.33% of the recovery. If your case goes to trial, the fee is 40%. We advance the costs of litigation — expert fees, filing fees, discovery costs — and those costs are repaid from the recovery. You do not write us a check. You do not pay hourly. The only way we get paid is if you get paid. Contact us at 1-888-ATTY-911 for a free, confidential consultation.
Si Su Familia Usó Polvo de Talco — Información en Español
Si usted o un ser querido usó polvo de talco de Johnson & Johnson durante años y luego desarrolló mesotelioma o cáncer de ovario, es posible que tenga un caso contra la compañía. La ley de California le da un tiempo limitado para presentar una reclamación — generalmente dos años desde el diagnóstico o desde la fecha del fallecimiento. Pero ese tiempo se está agotando, y la evidencia desaparece más rápido que el plazo legal.
Lo más urgente es preservar la evidencia. Guarde cualquier envase de polvo de talco que aún tenga — no lo abra, no lo agite, póngalo en una bolsa sellada. Pida por escrito al hospital que conserve las muestras de tejido de la biopsia o autopsia. Reúna cualquier recibo, fotografía, o testimonio de familiares que pueda demostrar qué producto se usó, durante cuántos años, y con qué frecuencia.
Nosotros hablamos Español. Lupe Peña, abogado de nuestro equipo, es completamente bilingüe y puede evaluar su caso en español sin intérprete, sin costo, y sin obligación. Llámenos al 1-888-ATTY-911. La consulta es gratis. No le cobramos nada a menos que ganemos su caso. Su familia merece respuestas en su propio idioma, y nosotros se las damos.
Why Our Firm — Ralph Manginello and Lupe Peña
Ralph Manginello has spent 27-plus years in courtrooms, including federal court. He was a journalist before he was a lawyer — a reporter who learned that the truth is more valuable than the pitch, and that a story told with facts beats a story told with adjectives. He carries that into every case. He is admitted to the U.S. District Court for the Southern District of Texas and handles cases in California through local counsel and pro hac vice admission where required. He does not tell families what they want to hear. He tells them what the law, the evidence, and the medicine actually support — and then he fights for it.
Lupe Peña spent years inside a national insurance-defense firm. He sat in the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He knows how the reserve is set in the first 48 hours, how the first settlement offer is calculated, and the difference between what an insurer says a case is worth and what a jury says it is worth. Now he uses that knowledge for injured clients. He is fluent in Spanish and conducts full consultations without an interpreter. He is a third-generation Texan, and he treats every family that walks through our door the way he would want his own family treated — with honesty, with competence, and with the understanding that what happened to them is not just a file number.
We handle wrongful death and product liability cases in California. The firm has recovered more than $50 million for clients across its practice — a marketing aggregate, not a guarantee. Past results depend on the facts of each case and do not guarantee future outcomes. What we guarantee is this: we will tell you the truth about your case, we will preserve your evidence before it disappears, and we will not accept a fraction of what your case is worth unless you decide that fraction is enough.
The Bottom Line — What the 2026 Split Verdicts Mean for You
The split verdicts of 2026 are not a reason to give up, and they are not a reason to assume victory. They are a reason to understand exactly what kind of fight this is — a fight where the outcome depends on the disease, the venue, the evidence, and the preparation.
If your family is dealing with mesothelioma after decades of baby powder use — the same fact pattern that produced the $32 million Lozano verdict — you have the strongest type of talc case there is. The science is on your side. The question is whether you can prove specific causation, and that depends on whether the pathology tissue is preserved and whether the exposure history is documented.
If your family is dealing with ovarian cancer, the road is harder but not closed. The December 2025 $40 million verdict proves that Los Angeles juries will find for plaintiffs in ovarian cancer cases when the evidence is strong. The June 5 defense verdict proves they will not when it is not.
Either way, the evidence is dying. The powder container in the bathroom. The tissue block in the hospital freezer. The memory of your mother’s morning routine. Every day that passes, the proof gets a little weaker — not because the harm is any less real, but because the physical and documentary record of it is fading.
Call us at 1-888-ATTY-911. The consultation is free. The call is confidential. We do not get paid unless we win your case. And if you are not sure whether you have a case — call anyway. Finding out that you do not is better than finding out too late that you did.
Hablamos Español. Free consultation. No fee unless we win. 1-888-ATTY-911.